Bottom Line Inc

Jumping the Gun on Personalized Cancer Medicine


Personalizing cancer treatment based on the genetic map of the individual is on the cutting edge of medicine. But some oncologists may be jumping the gun, according to a clinical trial published in Lancet Oncology. They’re prescribing these personalized—and expensive—cancer drugs for patients even when they haven’t been studied for those particular cancers. It’s called off-label use. But the results are no better than with conventional chemotherapy.

Date: October 8, 2015 Publication: Bottom Line Health
Keep Scrolling for related content View Comments